東星醫療(301290.SZ):暫無與美國的直接外貿業務
格隆匯4月11日丨東星醫療(301290.SZ)在投資者互動平台表示,公司目前暫無與美國的直接外貿業務,美國關税政策波動對公司業務的影響有限。公司目前主營業務收入90%以上來源於國內市場,外銷收入佔比較小且主要集中在歐洲、南美洲以及“一帶一路”沿線國家及地區,近幾年未對美國開展出口業務。公司所處微創外科醫療器械領域目前國產化進程正在穩步推進中,主要競爭對手如美敦力、強生等均為美國品牌。公司將持續跟蹤關税相關政策,審慎評估相關風險及潛在的機遇,並與客户保持密切溝通,通過制定靈活的市場策略,集中資源在技術含量較高、由海外廠商佔據主要市場份額的腔鏡吻合器領域進行技術研發突破,憑藉紮實的產品質量、個性化的產品優化改良、成熟的營銷渠道、價格優勢進行有效競爭,提升國產品牌的市場佔有率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.